Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience

Clicks: 276
ID: 274757
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #2 of 25 articles by views in acta haematologica

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Lenalidomide is an immunomodulatory drug administered orally in the treatment of multiple myeloma. Some elderly patients require a reduced lenalidomide dose because of comorbidities and/or adverse events. This study investigated the actual dose of lenalidomide ...
Reference Key
nomura2017actarealistic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Aya Nakaya, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Yoshiko Azuma, Yukie Tsubokura, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura;Aya Nakaya;Shinya Fujita;Atsushi Satake;Takahisa Nakanishi;Yoshiko Azuma;Yukie Tsubokura;Masaaki Hotta;Hideaki Yoshimura;Kazuyoshi Ishii;Tomoki Ito;Shosaku Nomura;
Journal acta haematologica
Year 2017
DOI
10.1159/000477792
URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872556/?report=classic
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.